JP2015513314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513314A5 JP2015513314A5 JP2014553490A JP2014553490A JP2015513314A5 JP 2015513314 A5 JP2015513314 A5 JP 2015513314A5 JP 2014553490 A JP2014553490 A JP 2014553490A JP 2014553490 A JP2014553490 A JP 2014553490A JP 2015513314 A5 JP2015513314 A5 JP 2015513314A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- fusion protein
- seq
- immunogenic fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims description 135
- 108020001507 fusion proteins Proteins 0.000 claims description 106
- 102000037865 fusion proteins Human genes 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 239000012634 fragment Substances 0.000 claims description 71
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 229960005486 vaccine Drugs 0.000 claims description 32
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 230000005757 colony formation Effects 0.000 claims description 3
- 230000008816 organ damage Effects 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589267P | 2012-01-20 | 2012-01-20 | |
| US61/589,267 | 2012-01-20 | ||
| PCT/US2013/022309 WO2013109995A2 (en) | 2012-01-20 | 2013-01-18 | Fused antigen vaccines and compositions against streptococcus pneumoniae |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091198A Division JP2017160238A (ja) | 2012-01-20 | 2017-05-01 | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513314A JP2015513314A (ja) | 2015-05-07 |
| JP2015513314A5 true JP2015513314A5 (OSRAM) | 2016-05-12 |
| JP6379041B2 JP6379041B2 (ja) | 2018-08-22 |
Family
ID=48799816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553490A Expired - Fee Related JP6379041B2 (ja) | 2012-01-20 | 2013-01-18 | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 |
| JP2017091198A Pending JP2017160238A (ja) | 2012-01-20 | 2017-05-01 | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091198A Pending JP2017160238A (ja) | 2012-01-20 | 2017-05-01 | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9765125B2 (OSRAM) |
| EP (1) | EP2804627B1 (OSRAM) |
| JP (2) | JP6379041B2 (OSRAM) |
| AU (1) | AU2013209513B2 (OSRAM) |
| CA (1) | CA2897020A1 (OSRAM) |
| WO (1) | WO2013109995A2 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4272750A3 (en) | 2013-02-07 | 2024-01-24 | Children's Medical Center, Corp. | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| EP3387006A4 (en) * | 2015-12-10 | 2019-05-08 | National Research Council of Canada | LIPIDATED STREPTOCOCCUS PNEUMONIAE |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| CN106822885B (zh) * | 2017-02-16 | 2020-06-30 | 清华大学 | 肺炎链球菌疫苗 |
| CA3119865A1 (en) * | 2018-11-23 | 2020-05-28 | Strike Pharma Ab | Bi-specific conjugates |
| WO2025012364A1 (en) * | 2023-07-12 | 2025-01-16 | Virometix Ag | Compositions of pneumococcal antigens |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| US5371197A (en) | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| GB0107658D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| CA2444133A1 (en) * | 2001-04-16 | 2002-10-24 | Wyeth Holdings Corporation | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| EP2275128B1 (en) | 2002-04-02 | 2013-10-16 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| WO2006084466A2 (en) | 2005-02-11 | 2006-08-17 | Ace Biosciences A/S | Surface-located streptococcus pneumoniae polypeptides |
| DK2054431T3 (da) * | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| WO2009023300A2 (en) | 2007-04-13 | 2009-02-19 | The Board Of Regents Of The University Of Oklahoma | Mutants of cholesterol-dependent cytolysins and uses thereof |
| SG10201403702SA (en) * | 2009-06-29 | 2014-09-26 | Genocea Biosciences Inc | Vaccines and compositions against streptococcus pneumoniae |
| MY163871A (en) * | 2011-01-20 | 2017-10-31 | Genocea Biosciences Inc | Vaccines and compositions against streptococcus pneumoniae |
| US9181308B2 (en) | 2011-03-28 | 2015-11-10 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| WO2013134656A1 (en) * | 2012-03-09 | 2013-09-12 | Genocea Biosciences, Inc. | Induction of th17 immune response |
-
2013
- 2013-01-18 EP EP13738798.1A patent/EP2804627B1/en active Active
- 2013-01-18 US US14/373,179 patent/US9765125B2/en not_active Expired - Fee Related
- 2013-01-18 JP JP2014553490A patent/JP6379041B2/ja not_active Expired - Fee Related
- 2013-01-18 CA CA2897020A patent/CA2897020A1/en not_active Abandoned
- 2013-01-18 WO PCT/US2013/022309 patent/WO2013109995A2/en not_active Ceased
- 2013-01-18 AU AU2013209513A patent/AU2013209513B2/en not_active Ceased
-
2017
- 2017-05-01 JP JP2017091198A patent/JP2017160238A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westritschnig et al. | A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers | |
| JP2023162283A5 (OSRAM) | ||
| JP2015513314A5 (OSRAM) | ||
| Romano et al. | Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines | |
| US20150197558A1 (en) | Binding moieties for biofilm remediation | |
| JP2012524733A5 (OSRAM) | ||
| RU2015122368A (ru) | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа | |
| Basset et al. | Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein | |
| JP2012532134A5 (OSRAM) | ||
| De Amicis et al. | Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes | |
| He et al. | A recombinant truncated surface immunogenic protein (tSip) plus adjuvant FIA confers active protection against Group B streptococcus infection in tilapia | |
| JP2013517783A5 (OSRAM) | ||
| JP2013512889A5 (OSRAM) | ||
| JP2013520487A5 (OSRAM) | ||
| JP2016504993A5 (OSRAM) | ||
| Guo et al. | Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection | |
| Qian et al. | Salmonella flagellin is a potent carrier–adjuvant for peptide conjugate to induce peptide-specific antibody response in mice | |
| RU2015141214A (ru) | Вакцины против Chlamydia sp. | |
| Lu et al. | Protective immune responses elicited by fusion protein containing PsaA and PspA fragments | |
| Vadesilho et al. | Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae | |
| Sharma et al. | Identification and immunogenic potential of B cell epitopes of outer membrane protein OmpF of Aeromonas hydrophila in translational fusion with a carrier protein | |
| WO2016154491A1 (en) | Binding moieties for biofilm remediation | |
| WO2017192594A1 (en) | Binding moieties for biofilm remediation | |
| JP2017513849A5 (OSRAM) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины |